Cytrellis Expands ellacor Micro-Coring Technology to Korea

Boston, Massachusetts, U.S., September 30, 2026

ellacor Technology Targets Facial Wrinkles

The ellacor Micro-Coring System uses a proprietary approach known as Micro-Coring, which creates numerous tiny openings in the skin to remove small columns of tissue. Unlike conventional surgical procedures, the technology is designed to remove tissue without requiring traditional incisions, sutures or significant surgical excision. The controlled removal of micro-cores is intended to stimulate the body’s natural wound-healing response and support collagen remodeling and skin rejuvenation. Cytrellis developed the technology as an alternative approach for patients seeking treatment for facial wrinkles without undergoing conventional surgical procedures. The system is particularly focused on moderate to severe wrinkles, including wrinkles that may be difficult to address using less invasive aesthetic treatments. By precisely removing micro-columns of skin, Micro-Coring is designed to create a controlled remodeling process while preserving the surrounding tissue. The technology has attracted interest within the rapidly expanding medical aesthetics and energy-free skin-remodeling market. Unlike laser- or energy-based resurfacing approaches, Micro-Coring relies on mechanical removal of tissue through specialized micro-coring technology. This differentiating mechanism is an important component of Cytrellis’ strategy for expanding treatment options in aesthetic dermatology.

South Korea Partnership Expands Global Reach

The new partnership will support the commercialization of ellacor in South Korea, giving Cytrellis an opportunity to expand its presence in a market recognized for its strong medical aesthetics sector. South Korea has developed a significant ecosystem around dermatology, cosmetic medicine and aesthetic procedures, creating a strategic market for innovative technologies focused on facial rejuvenation. Through the partnership, Cytrellis expects to work with its local commercial partner to support market development, physician adoption and availability of the ellacor system. The collaboration is intended to leverage local expertise while introducing Cytrellis’ Micro-Coring platform to qualified aesthetic medical professionals in the country. International commercialization agreements can play an important role in helping medical technology companies expand beyond their initial markets. For Cytrellis, the South Korea agreement builds on its broader efforts to establish ellacor as a differentiated aesthetic medical technology for patients seeking minimally invasive approaches to facial skin rejuvenation.

Cytrellis Advances Minimally Invasive Aesthetics

The commercialization agreement underscores Cytrellis’ focus on developing minimally invasive aesthetic technologies that can address visible signs of skin aging. The company’s Micro-Coring platform is designed around controlled tissue removal rather than thermal energy, offering a distinct technological approach to facial wrinkle treatment. The expansion into South Korea also reflects the continuing development of the global medical aesthetics market, where physicians and patients are increasingly evaluating procedures that offer visible results while reducing the invasiveness associated with traditional surgery. Technologies that can provide controlled tissue remodeling through minimally invasive procedures are becoming an important area of innovation within aesthetic medicine.

For cGxP.wire, the announcement represents a relevant MedTech commercialization and international expansion story, particularly because it involves the introduction of an established aesthetic medical technology into a new geographic market. The partnership demonstrates Cytrellis’ continued efforts to broaden access to ellacor Micro-Coring Technology and strengthen its international commercial footprint.

Source: Cytrellis press release